UPDATE : Monday, September 7, 2020
상단여백
Daewoong ends P3 trial for drug treating gastroesophageal reflux disease
Daewoong Pharmaceutical said that it has completed the phase 3 clinical tri...
by Lee Han-soo  |  2019-11-27 18:21
라인
Vivozon stops short of meeting primary endpoint for P2b trial of nonnarcotic analgesics
Vivozon said that it has obtained good clinical results from the U.S. phase...
by Lee Han-soo  |  2019-11-26 18:48
라인
Amgen releases analysis result showing benefits of LDL-C treatment
Amgen Korea said it has presented the analysis of its high cholesterol (LDL...
by Lee Han-soo  |  2019-11-26 17:05
라인
Roche’s flu treatment Xofluza wins approval
A new influenza treatment has arrived in Korea in over 20 years.The Ministr...
by Kim Yun-mi  |  2019-11-26 16:08
라인
Immunotherapies give hope for esophageal cancer patients
In curing esophageal cancer, there has been no treatment option other than ...
by Kim Yun-mi  |  2019-11-26 15:37
라인
GC Labcell hands over NK cell-treating tech to US lab
GC Labcell said it has transferred its natural killer (NK) cell treatment t...
by Lee Han-soo  |  2019-11-26 15:33
라인
SK Biopharm to speed up global advance through XCOPRI’s launch
SK Biopharmaceuticals will launch its antiepileptic drug, XCOPRI, in the se...
by Lee Han-soo  |  2019-11-26 14:16
라인
Huons Global wins KGMP certification for BTX plant
Huons Global said that the Ministry of Food and Drug Safety has granted the...
by Lee Han-soo  |  2019-11-25 16:00
라인
Gtree enrolls 200 patients for US trial of dry eye treatment
ReGenTree, the U.S. subsidiary of Gtree BNT, said that it has managed to en...
by Lee Han-soo  |  2019-11-25 14:49
라인
Daewoong renews EU GMP certification for BTX plant
Daewoong Pharmaceutical said that it has renewed its EU good manufacturing ...
by Lee Han-soo  |  2019-11-25 11:55
라인
SK Biopharm's antiepileptic drug is 1st local medicine to win FDA nod independently
SK Biopharmaceuticals' XCOPRI, a treatment for partial-onset seizures i...
by Lee Han-soo  |  2019-11-22 17:03
라인
Bridge Biotherapeutics aims to become global NRDO company
Bridge Biotherapeutics revealed its goal to become Korea's top no resea...
by Lee Han-soo  |  2019-11-22 15:10
라인
‘SGLT-2 inhibitor may prevent retinopathy in type-2 diabetes’
Researchers at Ajou University Hospital said sodium-glucose cotransporter-2...
by Lee Han-soo  |  2019-11-21 15:21
라인
‘Sprycel showed longer efficacy than nilotinib for chronic myeloid leukemia’
Bristol-Myers Squibb (BMS) has published the results of an observational st...
by Lee Han-soo  |  2019-11-21 14:26
라인
CJ HealthCare to export gastric acid blocker to Thailand
CJ HealthCare said Thursday that it planned to export K-Cab (Ingredient: te...
by Lee Han-soo  |  2019-11-21 10:54
라인
‘Japan much advanced than Korea in ALK-positive NSCLC treatment’
Japan moved fast to authorize to use lorlatinib, a third-generation targete...
by Kim Yun-mi  |  2019-11-20 16:16
라인
Remed aims to expand global presence through IPO
Remed expressed its aspiration to become a global leader in the newly emerg...
by Lee Han-soo  |  2019-11-20 15:30
라인
PharmAbcine registers 1st patient for phase-2 trial on olinvacimab
PharmAbcine, a developer of antibody drugs, said it has registered the firs...
by Jeong Sae-im  |  2019-11-19 17:18
라인
‘Udenafil improved exercise in single ventricle heart disease’
Mezzion Pharma said its investigational drug udenafil improved exercise cap...
by Jeong Sae-im  |  2019-11-18 14:48
라인
“Xalkori-Alecensa sequential therapy advantageous in duration of treatment”
Given the licensing and insurance system in Korea, the Xalkori-Alecensa seq...
by Kim Yun-mi  |  2019-11-15 17:48
여백
여백
여백
Back to Top